Nizatidine, an H2‐Receptor Antagonist: Disposition and Safety in the Elderly

John T. Callaghan, Alan Rubin, Mary Pat Knadler, Richard F. Bergstrom

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Nizatidine is an orally active H2‐receptor blocker. Its disposition and safety in eight young and 12 elderly volunteers were investigated. Single oral doses of nizatidine were administered: from 100 mg to 300 mg in the elderly, and from 100 mg to 350 mg in the young. The nizatidine AUC was directly proportional to dose for both groups. Calculated pharmacokinetic variables in the elderly vs. the young were t1/2 = 1.9 vs. 1.6 hr; CLp/f = 32 vs. 40 L/hr, and Vdβ/f = 1.2 vs. 1.3 L/kg. The impaired renal function of some elderly volunteers prolonged nizatidine elimination and lowered its clearance. Renal impairment rather than advanced age per se was the predominant factor in decreasing the nizatidine elimination rate. Because Clcr correlated directly with nizatidine renal clearance, Clcr values may be used to estimate nizatidine dosage reductions in renal insufficiency. During the trial, no serious adverse effects occurred. 1987 American College of Clinical Pharmacology

Original languageEnglish (US)
Pages (from-to)618-624
Number of pages7
JournalThe Journal of Clinical Pharmacology
Issue number8
StatePublished - Aug 1987

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Nizatidine, an H<sub>2</sub>‐Receptor Antagonist: Disposition and Safety in the Elderly'. Together they form a unique fingerprint.

Cite this